Anzeige
Mehr »
Sonntag, 07.06.2026 - Börsentäglich über 12.000 News
Breaking News: Nasdaq Quantencomputer Play mit riesigem Kurspotential!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9XF | ISIN: US0906556065 | Ticker-Symbol: 9OF
Tradegate
05.06.26 | 18:22
0,334 Euro
-6,70 % -0,024
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIORESTORATIVE THERAPIES INC Chart 1 Jahr
5-Tage-Chart
BIORESTORATIVE THERAPIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3480,36206.06.
0,3340,38005.06.

Aktuelle News zur BIORESTORATIVE THERAPIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.05.BioRestorative Therapies, Inc. - 8-K, Current Report5
BIORESTORATIVE THERAPIES Aktie jetzt für 0€ handeln
27.05.BioRestorative Therapies: Aktie springt nach Einstieg von Aktivist Kaos Kapital12
27.05.Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)296Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders MIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos...
► Artikel lesen
26.05.BioRestorative Therapies, Inc: BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data616Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting...
► Artikel lesen
15.05.Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates3
14.05.BioRestorative Therapies, Inc. - 10-Q, Quarterly Report1
13.05.BioRestorative presents data on stem cell-derived exosomes2
13.05.BioRestorative Therapies, Inc: BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals1
07.05.BioRestorative Therapies, Inc: BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease359Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting...
► Artikel lesen
01.05.BioRestorative Therapies, Inc. - 8-K, Current Report1
30.04.BioRestorative to present clinical, preclinical data at ISCT3
30.04.BioRestorative Therapies, Inc: BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform5
23.04.BioRestorative Therapies, Inc. - 8-K, Current Report-
21.04.BioRestorative kooperiert mit renommiertem Dermatologen für klinische Hautpflegestudie2
07.04.BioRestorative partners with 203 Creates for skincare brand launch3
07.04.BioRestorative Therapies, Inc: BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform1.682Partnership to drive brand architecture, go-to-market execution, and global launch of the Company's product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026 (GLOBE...
► Artikel lesen
30.03.BioRestorative Therapies, Inc: BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease196Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem...
► Artikel lesen
29.03.BioRestorative Therapies: EPS übertrifft Schätzungen um 0,01 $ - Umsatz schlechter als erwartet4
26.03.BioRestorative Therapies, Inc. - 10-K, Annual Report11
19.03.BioRestorative Therapies, Inc: BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease14
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1